2 Under-the-Radar Biotech Stocks to Buy in 2023

There are reasons to be wary of the stock market right now. Chief among them is the fact that the economy continues to be somewhat uncertain, making it difficult to predict how things will develop in the next year. But the short-term prospects of equities are almost always challenging to predict.

Although the current environment has some particularities, it's always essential to focus on the long run when looking for stocks in which to invest. With that said, let's consider two biotech stocks, neither of which is a household name, that could deliver solid returns over the next five years and more: (NASDAQ: EXEL) and Sarepta Therapeutics (NASDAQ: SRPT). 

Oncology is one of the most fiercely competitive therapeutic areas in the biotech industry. Exelixis, a mid-cap biotech, is just a small player in the field. However, it has a major claim to fame. The company's crown jewel, Cabometyx, is the top-prescribed tyrosine kinase inhibitor -- a kind of therapy that specifically targets and attacks cancer cells -- in renal cell carcinoma (RCC, a type of kidney cancer) and second-line hepatocellular carcinoma (HCC, a variety of liver cancer).

Continue reading

Source Fool.com